🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "huge turning point" in the effort against drug-resistant strains of the pathogen, according to health experts.

An International Health Concern

The sexually transmitted infection are escalating globally, with figures suggesting over 82 million new cases each year. Notably increased rates are seen in Africa and nations within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune step in the face of rising global incidence, the spread of superbugs and the extremely scarce therapeutic options at this time.”

Medical experts are particularly alarmed about the rise in drug-resistant strains. The WHO has listed it as a "high-priority threat". A tracking program showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Therapies Receive Clearance

One new antibiotic, marketed under the name a brand name, was cleared by the American regulatory agency in December for use against gonorrhoea. This infection can lead to major issues, including the inability to conceive. Researchers hope that focused deployment of this new drug will help slow the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GSK, also received approval in close succession. This medication, which is additionally indicated for urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to develop it.

“This milestone marks a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Clinical Trial Data and Worldwide Availability

According to results released by a prominent scientific publication, zoliflodacin eradicated the vast majority of cases of the STI. This establishes an comparable level with the existing first-line therapy, which combines an injection and a pill. The trial involved over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the rights to register and commercialise the drug in a wide range of low-income and middle-income countries.

Doctors treating patients have voiced hope. The availability of a single-dose, oral treatment such as this is seen as a "critical tool" for managing the epidemic. This is considered crucial to lessen the impact of the infection for people and to prevent the spread of highly drug-resistant gonorrhoea globally.